The need for comparative data in spondyloarthritis

Autor: Ernest Choy, Xenofon Baraliakos, Frank Behrens, Salvatore D’Angelo, Kurt de Vlam, Bruce W. Kirkham, Mikkel Østergaard, Georg A. Schett, Michael Rissler, Kamel Chaouche-Teyara, Chiara Perella

Publikováno v: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-6 (2019)

Abstract Spondyloarthritis comprises a group of inflammatory diseases, characterised by inflammation within axial joints and/or peripheral arthritis, enthesitis and dactylitis. An increasing number of biologic treatments, including biosimilars, are a

Externí odkaz: https://doaj.org/article/bcfaeb54cfae4cbaa978343733a93070

Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population

Autor: Christian Sieder, Roberto Orsenigo, Matthias Augustin, Sven Gathmann, Maria Polina Konstantinou, Ulrich Mrowietz, Sascha Gerdes, Esteban Daudén, Daniel Baeumer, Michael Rissler

Publikováno v: Journal of the European Academy of Dermatology and Venereology. 34:2548-2556

Introduction Psoriatic disease is associated with considerable impairment of Quality of Life (QoL). The PROSE study (NCT02752776) examined the impact of secukinumab on patient-reported outcomes in patients with moderate-to-severe psoriasis (PsO) stra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3682e85048fda1ec42218e7c301e4a22
https://doi.org/10.1111/jdv.16400

Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study

Autor: Christian Sieder, Michael Rissler, Ulrich Mrowietz, A D Burden, Hervé Bachelez, Roberto Orsenigo, Piotr Jagiello

Publikováno v: Journal of the American Academy of Dermatology. 84:552-554

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cfe26d67956cbec2172bc967f4a0a99a
https://doi.org/10.1016/j.jaad.2020.06.038

P188 Secukinumab provides significant improvement of spinal pain and lowers disease activity in patients with axial spondyloarthritis: 24-week results from a randomised controlled Phase 3b trial

Autor: Agnieszka Zielińska, Chiara Perella, Denis Poddubnyy, Effie Pournara, Sanchayita Sadhu, Barbara Schulz, Helena Marzo-Ortega, Michael Rissler, Asta Baranauskaite

Publikováno v: Rheumatology. 60

Background/Aims SKIPPAIN (NCT03136861) is the first randomised controlled study involving a biological disease-modifying anti-rheumatic drug, with a primary endpoint of spinal pain at Week 8 in patients with axial spondyloarthritis (axSpA; ankylosing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cc8d38b0d78a25e0a384fdaa856249e
https://doi.org/10.1093/rheumatology/keab247.183

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Autor: Xenofon Baraliakos, Michael Rissler, Sławomir Jeka, Effie Pournara, Antonio Mera-Varela, Laura C Coates, Chiara Perella, Laure Gossec, Salvatore D'Angelo, Kriti Nagar, Barbara Schulz

Publikováno v: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2020, 80 (5), pp.582-590. ⟨10.1136/annrheumdis-2020-218808⟩
Annals of the Rheumatic Diseases, 2020, 80 (5), pp.582-590. ⟨10.1136/annrheumdis-2020-218808⟩

International audience; Objectives MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA). Met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c404c72168bb451dc0e582833731469b
https://pubmed.ncbi.nlm.nih.gov/33334727